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Abstract  1 
Background: Age-related sarcopenia describes loss of muscle strength and often 2 
accompanies an increase in adiposity in elderly participants.  3 
Objectives: We examined the association of sarcopenic obesity, and changes in muscle 4 
strength and weight with risk of mortality. 5 
Design: Participants were 6,864 community dwelling men and women (mean±SD age 66.2 ± 6 
9.5 years, 45.6% men) from the English Longitudinal Study of Ageing. Handgrip strength and 7 
body mass index were measured at baseline and at four years follow-up. Individual 8 
participant data were linked with death records from National Health Service registries. 9 
Sarcopenic obesity was defined as obese individuals (body mass index [BMI] ≥ 30 kg/m2) in 10 
the lowest tertile of sex specific grip strength (<35.3 kg men; < 19.6kg women). 11 
Results: Over an average follow up of 8 years there were 906 deaths. Compared with the 12 
reference group (normal BMI and highest hand grip tertile), the risk of all-cause mortality 13 
increased with reducing grip strength within each BMI category. For participants in the 14 
lowest hand grip tertile there was little difference in risk between normal BMI (Hazard 15 
ratio=3.25; 95% CI, 1.86, 5.65), overweight (2.50;1.44, 4.35), and obese (2.66; 1.86, 3.80), 16 
after adjustment for covariates. Compared to participants with stable weight and grip 17 
strength, risk of all-cause mortality was significantly greater in those experiencing weight 18 
loss over 4 years (2.21;1.32, 3.71) and reduced hand grip strength (1.53;1.07, 2.17), with the 19 
highest risk in those with weight loss and reduced strength (3.77; 2.54, 5.60). 20 
Conclusion: Sarcopenic obesity did not confer any greater risk than sarcopenia alone. 21 
Weight loss in combination with sarcopenia presented the greatest risk of mortality. 22 
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Introduction 23 
Age-related sarcopenia is a syndrome characterized by a progressive loss of skeletal muscle 24 
mass and quality (or strength) resulting in impaired physical performance (1,2). Age-related 25 
loss of muscle mass is often accompanied by gain in adipose tissue, thus sarcopenic obesity 26 
describes a clinical entity in which these two states are thought to act together to increase 27 
risk more than the additive effect of the two factors alone in the pathophysiology of both 28 
metabolic, functional impairments, and mortality risk (3-9).  29 
There is limited evidence on the association between sarcopenic obesity and mortality, 30 
although data from several cohort studies suggest that sarcopenic obesity does not confer 31 
any greater risk than sarcopenia alone (8,9). In constrast, other cohort data have shown that 32 
the combination of obesity and high hand grip strength is associated with lower risk of 33 
mortality in older adults (10). Nevertheless, when obesity was defined from waist 34 
circumference and high triglycerides, the combination of abdominal obesity and sarcopenia 35 
was associated with the highest risk of mortality (11).   These studies, however, relied on a 36 
single baseline clinical visit to assess sarcopenia and body composition, and did not examine 37 
changes over time. Indeed, changes in sarcopenia status can be best captured using repeat 38 
longitudinal clinical assessments. The aim of our study was therefore to first examine the 39 
association of sarcopenia and obesity at baseline with mortality over 8 years follow up; 40 
second we examined associations between changes in muscle strength and weight on risk of 41 
mortality. Analyses were performed on a well characterised community sample of older 42 
adults. In our study we defined “sarcopenia” using the lowest sex specific tertile of hand grip 43 
strength. 44 
Methods  45 
4 
 
 
 
Study sample and procedures 46 
The English Longitudinal Study of Ageing (ELSA) is an ongoing cohort study of a nationally 47 
representative sample of the English population born on or before 29 February 1952 living 48 
in private households (12). A multi-stage stratified probability sampling method was used to 49 
recruit the sample.  Participants gave full, informed written consent to take part in the study 50 
and ethical approval was obtained from the London Multi-Centre Research Ethics 51 
Committee. For the purposes of the present analyses, data collected in 2004/05 (wave 2) 52 
were used as the baseline, as this was the first occasion on which clinical information was 53 
gathered. An identical clinical assessment was repeated four years later at wave 4 (2008/09) 54 
and the individual participant data were linked with death records from National Health 55 
Service registries for all consenting respondents (96.5% of the sample) up to February 2012. 56 
For the key exposure measure, grip strength, there were no upper age limits although 57 
respondents were excluded if they had swelling or inflammation, severe pain, or a recent 58 
injury or surgery to the hand in the preceding 6 months.  59 
 60 
Handgrip and body mass index  61 
Handgrip strength (kg) of the dominant hand was assessed using the Smedley hand-held 62 
dynamometer (Stoelting Co, IL, USA ), using the average of three measurements. 63 
Participants were required to hold the device at a right angle to their body and exert 64 
maximum force for a couple of seconds when instructed. Successive trials were alternated 65 
between dominant and non-dominant hands. Nurses measured participants’ body weight 66 
without shoes and in light clothing to the nearest 0.1 kg using Tanita electronic scales 67 
(Tanita Co, IL, USA), and height was measured using a stadiometer with the Frankfurt plane 68 
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in the horizontal position; body mass index (BMI) was calculated using the standard formula 69 
[weight (kg)/height2 (m2)].  70 
 71 
Covariates  72 
At baseline, trained interviewers collected information on self –reported cigarette smoking 73 
(current, previous or non-smoker), the self –reported frequency of participation in physical 74 
activities (more than once per week, once per week, one to three times per month, hardly 75 
ever), self –reported physician-diagnosed cardiovascular diseases, longstanding illness, 76 
depressive symptoms (assessed using the self–reported 8-item Centre of Epidemiological 77 
Studies Depression (CES-D) scale (13). Based on previous work in ELSA showing robust dose-78 
response associations with mortality (14), physical activity was further categorised into 79 
three groups classified as: inactive (no moderate or vigorous at least once a week); 80 
moderate activity at least once a week (but no vigorous), and vigorous activity at least once 81 
a week. Depressive symptoms were categorised as a binary variable (CES-D score 0 – 3 [ref]; 82 
or > 3). Self-reported wealth was used as our measure of socioeconomic status.  The wealth 83 
variable comprised the total value of the participant’s home (excluding mortgage), financial 84 
assets such as savings, business assets, and physical wealth such as artwork or jewellery, 85 
which has been shown to best capture the material resources available to older adults (15). 86 
Wealth was grouped into quintiles relative to the ELSA sample. 87 
 88 
Statistical analysis 89 
We created sex specific tertiles of grip strength; the range of handgrip strength at baseline 90 
in men was 4 – 35.3 (median [IQR]= 29.7 [7.7]), 35.4 – 44.2 (39.7 [4.0]), >44.2 (48.7 [6.0]) kg 91 
for low, intermediate and high tertiles, respectively. The corresponding ranges in women 92 
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were 4 – 19.6 (16.0 [5.0]), 19.7 – 24.9 (22.3 [2.7]), >24.9 (28.3 [4.3]) kg, respectively. 93 
Sarcopenic obesity was defined as obese individuals (BMI ≥ 30 kg/m2) in the lowest tertile of 94 
sex specific grip strength (<35.3 kg men; < 19.6kg women). Non-obese were defined as BMI 95 
18.5 – 29.99   kg/m2 and underweight participants were excluded to prevent possible 96 
reverse causation (as underweight is often a marker of serious illness) (16). We used Cox 97 
proportional hazards regression models to examine associations between sarcopenic 98 
obesity and death. Age at death was recorded and years were the time scale for the follow-99 
up. For consenting participants with no record of an event, the data were censored at 100 
February 2012. The proportional hazards assumption was examined by using plots of the 101 
Nelson-Aalen cumulative hazard estimates. In preliminary analyses, there was no evidence 102 
of effect modification according to sex, thus data for men and women were pooled and sex-103 
adjusted. We estimated models that were initially adjusted for age and sex. The final models 104 
were additionally adjusted for physical activity, smoking, depressive symptoms, long 105 
standing illness, and wealth.  These covariates were selected a priori based on previous 106 
literature (8,9). The analyses described above were repeated using Foundation for the 107 
National Institutes of Health Biomarkers Consortium (FNIH) sex-specific handgrip strength 108 
cutoffs (men <26 kg; women <16kg) to define sarcopenia (1). We performed sensitivity 109 
analyses excluding participants who died in the first two years of follow up and those with 110 
doctor diagnosed cardiovascular diseases at baseline. In the final set of analyses we 111 
examined the association between changes in hand grip strength and weight on risk of 112 
mortality.  Weight change was defined as an increase or reduction in 5% of initial body mass 113 
(17), and loss of grip strength was defined as reduction in 5% of initial hand grip between 114 
clinical assessment waves 2 to 4. All analyses were conducted using SPSS (version 22). 115 
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Results  116 
A total of 8,688 participants (82% of wave 1 participants) attended the wave 2 (baseline) 117 
clinical assessment.  The analytic sample comprised 6,864 men and women (aged 66.2 ± 118 
(SD) 9.5 years, 45.6% men) (see Figure 1). Compared with the analytic sample, the excluded 119 
participants were older (66.2±9.5 vs. 70.7±11.4 yrs, p<0.001), less wealthy (lowest wealth 120 
quintile; 15.2 vs 21.4%, p<0.001), and less vigorously active (29.1 vs. 18.7%, p<0.001), 121 
although they reported similar prevalence of cardiovascular disease (18.0 vs 16.1%, p=0.17) 122 
and smoking (16.2 vs 18.2%, p=0.13). 123 
The baseline characteristics are displayed in Table 1. Participants in the highest tertile of 124 
grip strength (non-obese and obese) were younger than participants with medium and low 125 
grip strength. Non-obese participants with high grip strength were more physically active, 126 
wealthier, displayed lower levels of depressive symptoms and reported less disease than 127 
other participants. 128 
During an average follow up of 7.6 years (median, 8.1; range 0 – 8.1 yrs) there were 906 129 
deaths. We observed a “U”-shaped association between BMI and mortality, with the 130 
overweight category demonstrating lowest risk of mortality (see Supplemental Table 1). In 131 
comparison with the highest tertile for grip strength there was a linear increase (p-trend 132 
<0.001) in mortality risk for the middle (HR=1.71; 95% CI, 1.32, 2.21) and lower tertiles 133 
(2.20; 1.70, 2.85). 134 
Compared with the reference group (normal BMI and highest hand grip strength tertile), the 135 
risk of all-cause mortality increased with reducing grip strength within each BMI category. 136 
For participants in the lowest hand grip tertile there was little difference in risk between 137 
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normal BMI (3.25; 1.86, 5.65), overweight (2.50;1.44, 4.35), and obese (2.66; 1.86, 3.80), 138 
after adjustment for covariates (Table 2, Model 2). In additional analyses we categorised 139 
participants using FNIH sex-specific handgrip strength cut-offs (men <26 kg; women <16kg) 140 
to identify sarcopenia, and 12.7% of the sample met the threshold. Compared with the 141 
reference group (non-obese and non-sarcopenic), the increased risk of all-cause mortality 142 
was similar in sarcopenic (age/sex adjusted HR, 1.22; 1.02, 1.45) and in sarcopenic obese 143 
(1.22; 0.93, 1.61), although associations did not persist after adjustment for all covariates 144 
(physical activity, smoking, depressive symptoms, long standing illness, and wealth) 145 
(Supplemental Table 2). Results were similar in sensitivity analyses excluding participants 146 
who died in first two years of follow up and those with doctor diagnosed cardiovascular 147 
diseases at baseline (Supplemental Table 3). 148 
Around 11.5% of the sample gained weight and 12.0% lost weight over 4 years follow-up, 149 
and 52.8% experienced at least a 5% reduction in handgrip strength. Table 3 demonstrates 150 
that all-cause mortality risk was significantly greater in participants experiencing weight loss 151 
over 4 years (2.21; 1.32, 3.71) and reduced hand grip strength (1.53;1.07, 2.17), with the 152 
highest risk in those with weight loss and strength reduction (3.77; 2.54, 5.60). No excess 153 
risk was observed in either of the weight gain groups. Three measures were used to 154 
investigate biological interaction between weight loss and sarcopenia in relation to 155 
mortality (18): the relative excess risk due to interaction (RERI); the attributable portion due 156 
to interaction (AP); and the synergy index (S) (RERI and AP would be equal to 0 and S would 157 
be equal to 1 if there were no biological interaction). The interaction was modelled as 2 × 2 158 
categories, comprising a binary weight loss variable (yes or no) and binary grip strength loss 159 
variable (yes or no). Although there appeared to be some evidence of biological interaction, 160 
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(RERI=0.23, 95% CI: -1.56, 2.02; AP= 0.07, 95% CI: -0.46, 0.60;  S=1.11, 95% CI: 0.48, 2.55) 161 
the effect estimates were not statistically significant. 162 
Discussion  163 
The main aim of this study was to examine associations between sarcopenic obesity and 164 
mortality. A novel addition to the area was to examine the association between changes in 165 
muscle strength and weight on risk of mortality. Our main findings showed sarcopenic 166 
obesity did not confer any greater risk than sarcopenia alone. In fact, body mass index was a 167 
poor predictor of mortality. In contrast, using data from repeat clinical assessments, we 168 
showed that weight loss in combination with loss of muscle strength presented the greatest 169 
risk. Loss of lean muscle mass and gain in adiposity is considered a hallmark of ageing. That 170 
weight gain combined with loss of muscle strength was not associated with risk of mortality 171 
in the present study challenges commonly held belief in the area.  172 
Previous evidence has suggested that overweight and obesity are not as adverse in elderly 173 
populations (10,19), and that muscle mass may be more strongly associated with mortality 174 
than obesity (8,20). However, results may be biased when using BMI assessed from a single 175 
time point as morbidity is a positive function of the duration of obesity, and effects may be 176 
obscured when obese participants fall into normal weight categories due to rapid weight 177 
loss from underlying disease (21). In the present study obesity itself was not associated with 178 
mortality when compared to a normal weight reference category alone, although the results 179 
changed when the reference category was refined to include non-obese with grip strength 180 
in the highest tertile.  181 
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Low grip strength may be explained by factors other than low muscle mass, such as 182 
underlying disease and general health status (22). Indeed, many individuals with weakness 183 
may not have low muscle mass. This had led to suggestions of a distinct term, dynapenia 184 
(23). Nevertheless, associations between grip strength and mortality have been consistently 185 
observed in cohort studies (24), including some with follow-up of over 20 years in which the 186 
prevalence of sub-clinical disease and existing comorbidities at baseline was low. Data on 187 
skeletal muscle mass were not available in the present cohort and we relied on 188 
measurements of muscle strength alone. Nevertheless, while lean mass and strength 189 
(muscle quality) may not decline at the same rate, loss of lean mass is strongly associated 190 
with strength decline in both men and women (25). We used the suggested cut points for 191 
weakness according to the FNIH criteria (1). However, only 12.7% of the sample met the 192 
threshold for weakness based on their handgrip thus limiting our statistical power. Recent 193 
evidence has suggested aerobic fitness may have additive and multiplicative interactions 194 
with muscle strength in relation to all-cause mortality (26), although such data were not 195 
available in the present study. 196 
ELSA is a nationally representative cohort, although the present sample included younger 197 
and healthier participants than the overall cohort due to loss of older, more disadvantaged 198 
men and women. Thus the present findings might reflect a conservative estimate of the true 199 
effects. The covariates were self-reported, and imprecise measurement may have led to 200 
residual confounding.  201 
 202 
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In conclusion, sarcopenic obesity did not confer any greater mortality risk than sarcopenia 203 
alone in a sample of community dwelling older adults. Weight loss in combination with a 204 
reduction in muscle strength presented the greatest risk. 205 
 206 
 207 
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Table 1. Characteristics of the sample at baseline. Data presented as percentages within group 
unless stated 
Variable  Sex-specific hand grip tertile1 stratified by obesity 
Non-obese (BMI 18.5 – 29.99 Kg/m2) 
 
Obese (≥30 kg/m2) 
 High  Intermediate  Low High  Intermediate  Low 
N 1464 1625 1769 685 663 658 
Age, yrs 
(mean±SD) 
60.8± 6.2 65.5± 8.4 72.4± 10.1 60.6± 6.3 65.4± 8.0 70.2± 9.1 
Sex (% men)  38.3 50.5 50.3 40.9 45.6 38.1 
Physical activity 
Inactive  
Moderate  
Vigorous  
 
9.4 
47.7 
42.9 
 
14.5 
51.3 
34.3 
 
30.1 
50.3 
19.7 
 
17.7 
54.0 
28.3 
 
24.9 
52.0 
23.1 
 
41.8 
41.6 
16.6 
Smoking 
Never 
Ex-smoker 
Current  
 
40.3 
41.5 
18.2 
 
37.9 
45.3 
16.8 
 
34.3 
48.9 
16.8 
 
33.8 
51.5 
14.6 
 
37.4 
47.3 
15.3 
 
35.5 
51.4 
13.1 
Wealth2 quintile 
1st (poorest) 
2nd 
3rd 
4th 
5th (richest)  
 
7.7 
14.6 
21.1 
26.9 
29.6 
 
10.8 
17.2 
20.2 
24.5 
27.3 
 
21.0 
20.9 
20.0 
18.8 
19.4 
 
13.1 
17.1 
23.5 
23.6 
22.6 
 
17.8 
20.1 
22.5 
22.6 
17.0 
 
28.6 
22.3 
21.0 
16.6 
11.6 
Depressive 
symptoms  
CES-D score 0 - 3 
CES-D score >3  
 
 
89.9 
10.1 
 
 
88.4 
11.6 
 
 
81.7 
18.3 
 
 
86.9 
13.1 
 
 
86.1 
13.9 
 
 
78.6 
21.4 
Chronic illness 
None  
Yes  
 
59.2 
40.8 
 
52.2 
47.8 
 
37.6 
62.4 
 
47.9 
52.1 
 
40.7 
59.3 
 
26.7 
73.3 
Prevalent CVD3 
None  
Yes  
 
86.8 
13.2 
 
81.1 
18.9 
 
74.0 
26.0 
 
82.0 
18.0 
 
75.9 
24.1 
 
70.2 
29.8 
Body mass index, 
kg/m2 (mean± SD) 
25.8±2.5 25.7±2.6 25.4±2.7 33.9±3.8 33.8±3.9 33.9±3.8 
1In men, the range of handgrip strength at baseline was 4 – 35.3, 35.4 – 44.2, >44.2 kg for low, 
intermediate and high tertiles, respectively. The corresponding ranges in women were 4 – 19.6, 19.7 
– 24.9, >24.9 kg, respectively. 
2The wealth variable comprised the total value of the participant’s home (excluding mortgage), 
financial assets such as savings, business assets, and physical wealth such as artwork or jewellery, 
which was grouped into quintiles relative to the present sample. 
3doctor diagnosed cardiovascular diseases [CVD] (angina, heart disease, heart failure, heart murmur, 
arrhythmia, stroke) 
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Table 2. Hazard ratios (95% CI)1 for the association between hand grip strength and mortality 
stratified by obesity status, over 8 yrs follow-up (n=6,864).   
Grip strength tertile2 Normal BMI  
(18.5 – 24.99 
Kg/m2) 
Overweight  BMI  
(25.0 – 29.99 
Kg/m2) 
Obese BMI  
(≥ 30 Kg/m2) 
Model 1    
High  1.00 (reference) 0.98 (0.52, 1.87) 1.97 (1.27, 3.05) 
Intermediate  2.51 (1.41, 4.49) 2.00 (1.14, 3.51) 2.57 (1.76, 3.76) 
Low 3.91 (2.24, 6.80) 2.90 (1.67, 5.04) 3.31 (2.34, 4.72) 
Model 2    
High 1.00 (reference) 0.98 (0.52, 1.87) 1.81 (1.17, 2.81) 
Intermediate  2.43 (1.36, 4.44) 1.92 (1.09, 3.37) 2.23 (1.52, 3.26) 
Low 3.25 (1.86, 5.65) 2.50 (1.44, 4.35) 2.66 (1.86, 3.80) 
Model 1; Hazard ratios(HR) adjusted for age, sex.  
Model 2; adjusted for age, sex , physical activity, smoking, wealth, depressive symptoms, long 
standing illnesses. 
1 Cox proportional hazards regression models were used to analyse the data. 
2In men, the range of handgrip strength at baseline was 4 – 35.3, 35.4 – 44.2, >44.2 kg for low, 
intermediate and high tertiles, respectively. The corresponding ranges in women were 4 – 19.6, 19.7 
– 24.9, >24.9 kg, respectively. 
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Table 3. Hazard ratios (95% CI) for the association of 4 year changes in handgrip strength and weight 
with mortality (n=4,474)1.   
Weight change2 Grip strength change3 
Model 1 Stable (n=2110) Lost (n=2364) 
Stable (n=3422) 1.00 (reference) 1.54 (1.08, 2.18) 
Gain (n=514) 2.14 (1.11, 4.15) 1.91 (1.00, 3.69) 
Lost (n=538) 2.44 (1.47, 4.06) 4.18 (2.82, 6.18) 
Model 2   
Stable (n=3422) 1.00 (reference) 1.53 (1.07, 2.17) 
Gain (n=514) 1.84 (0.95, 3.58) 1.74 (0.90, 3.38) 
Lost (n=538) 2.21 (1.32, 3.71) 3.77 (2.54, 5.60) 
Model 1; Hazard ratios(HR) adjusted for age, sex.  
Model 2; adjusted for age, sex , physical activity, smoking, wealth, depressive symptoms, long 
standing illnesses. 
1 sample contains only participants that attended clinical assessments at both baseline (wave 2) and 
four years follow up (wave 4). 
2Weight change defined as increase or reduction in 5% of initial body mass between clinical 
assessment waves 2 to 4;  
3Loss of grip strength defined as reduction in 5% of initial grip measure between clinical assessment 
waves 2 to 4. Participants that increased grip strength were combined with those remaining stable. 
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Figure legend 
Figure 1.  Selection of participants 
